Gracell Biotechnologies Inc. (NASDAQ:GRCL) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET
Company Participants
Dr. William Cao - Founder, Chairman, and CEO
Dr. Martina Sersch - CMO
Dr. Kevin Xie - CFO
Conference Call Participants
Joe Catanzaro - Piper Sandler
Kelly Shi - Jefferies
Nick Abbott - Wells Fargo
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Gracell Biotechnologies First Quarter 2022 Conference Call. At this time, all participants are in listen-only mode. After opening remarks, we will open the call for your questions. Instructions for queuing up will be given at that time.
I would now like to turn the conference call over to Dr. Kevin Xie, CFO. Please go ahead.
Dr. Kevin Xie
Good morning, and welcome to Gracell's First Quarter 2022 Corporate Update Conference Call and Webcast. With me today are Gracell's Founder and Chief Executive Officer, Dr. William Cao; and our Chief Medical Officer, Dr. Martina Sersch. We're excited to discuss our innovative technologies and rich clinical pipeline of CAR-T therapies on today's call. We also look forward to sharing with you our recent business developments and upcoming objectives for 2022. After our formal remarks, we will conduct a question-and-answer session. This morning, Gracell issued a press release announcing unaudited financial results for the quarter ended March 31, 2021. We encourage everyone to read this press release, and would like to remind you that this call is being recorded for replay.
Please note that for certain information discussed on the call today, including financial data, clinical data, future plans of our programs, Gracell's management will be making forward-looking statements. Actual results could differ materially from these stated or implied by these forward-looking statements as a result of various important factors, and please refer to the Risk Factors section of our latest 20-F filings with SEC for a full disclosure of these risks and factors. The conference call contains time-sensitive information that is accurate only as of date of this live broadcast, May 16, 2022. Gracell undertakes no obligation to revise or update any forward-looking statements to reflect events and circumstances after the date of this conference call, except as may be required by securities laws.
I will now turn the call over to Gracell's CEO, Dr. William Cao. William?
Dr. William Cao
Thank you, Kevin, and again, welcome, everyone, to our first quarter 2022 corporate update conference call. Gracell has made substantial progress over the past quarter, and it continues to deliver across corporate, clinical, and operational initiatives. I will elaborate on some of the key achievements so far and anticipated milestones over the next few quarters. Following this, I will turn the call over to our CMO, Dr. Martina Sersch, to discuss our clinical development, and then turn to our CFO, Dr. Kevin Xie, to discuss financial results. We are dedicated to developing our rich clinical pipeline, with multiple clinical trials underway, including two R&D approved trials and several investigator-initiated trials, or IIT for short. We continue to advance the IITs for GC012F our autologous CAR-T therapeutic candidates, based on our FasTCAR, next-day manufacturing platform. As announced, we will be providing updates from two out of the IIT studies at medical meetings in June concurrently. And currently, we plan to file INDs in the US and in China for GC012F for the treatment of relapsed/refractory multiple myeloma or RRMM for short, during the second half of 2022. We are pleased to - that updated data from ongoing IIT evaluating GC012F for the treatment of RRMM, was selected as oral presentations next month at both conferences, ASCO 2022, and EHA 2022. We look forward to sharing more details when the abstracts were posted on ASCO’s and EHA’s websites on May 26. At EHA 2022, we also plan to present initial data from an ongoing IIT evaluating GC012F for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma, (R/R B-NHL. We are very excited about this data, as it is the first time that we’ll be disclosing data for NHL. This is yet another demonstration of our unwavering commitment in developing breakthrough cell therapies.